1. who have allergy to niclosamide and/or any of the treatment agents and/or any of the excipients of the products, 2. who is diagnosed as "severe or critical case" (e.g. pneumonia or severe pneumonia), 3. whose national early warning score 2 (news2) score is indicated as "urgent" or "emergency", 4. any history of bone marrow transplant, solid-organ transplant, immune compromising conditions, immunomodulatory therapy, haematologic malignancy, 5. who have multiple sclerosis, 6. who have electrolyte imbalance, chronic haemodialysis or glomerular filtration rate \< 30 30 ml/min/1.73m2, 7. who have history of serious cardiovascular diseases, 8. who are diagnosed with another ongoing viral infection other than sars cov-2, 9. who have macrophage activation syndrome, 10. who have a need for coagulopathy treatment, 11. who have severe liver disease, 12. who is pregnant or nursing, 13. who are not suitable to 1st articles of inclusion criteria, 14. who is not eligible to swallow oral medications, 15. who use vitamin c as supplementary medication during the study, 16. who are included in another trial.

1. who have allergy to niclosamide and/or any of the treatment agents and/or any of the excipients of the products, 2. who is diagnosed as "severe or critical case" (e.g. pneumonia or severe pneumonia), 3. whose national early warning score 2 (news2) score is indicated as "urgent" or "emergency", 4. any history of bone marrow transplant, solid-organ transplant, immune compromising conditions, immunomodulatory therapy, haematologic malignancy, 5. who have multiple sclerosis, 6. who have electrolyte imbalance, chronic haemodialysis or glomerular filtration rate \< 30 30 ml/min/1.73m2, 7. who have history of serious cardiovascular diseases, 8. who are diagnosed with another ongoing viral infection other than sars cov-2, 9. who have macrophage activation syndrome, 10. who have a need for coagulopathy treatment, 11. who have severe liver disease, 12. who is pregnant or nursing, 13. who are not suitable to 1st articles of inclusion criteria, 14. who is not eligible to swallow oral medications, 15. who use vitamin c as supplementary medication during the study, 16. who are included in another trial.

who have allergy to niclosamide and/or any of the treatment agents and/or any of the excipients of the products, who is diagnosed as "severe or critical case" (e.g. pneumonia or severe pneumonia), whose national early warning score 2 (news2) score is indicated as "urgent" or "emergency", any history of bone marrow transplant, solid-organ transplant, immune compromising conditions, immunomodulatory therapy, haematologic malignancy, who have multiple sclerosis, who have electrolyte imbalance, chronic haemodialysis or glomerular filtration rate < 30 30 ml/min/1.73m2, who have history of serious cardiovascular diseases, who are diagnosed with another ongoing viral infection other than sars cov-2, who have macrophage activation syndrome, who have a need for coagulopathy treatment, who have severe liver disease, who is pregnant or nursing, who are not suitable to 1st articles of inclusion criteria, who is not eligible to swallow oral medications, who use vitamin c as supplementary medication during the study, who are included in another trial.

who have allergy to niclosamide and/or any of the treatment agents and/or any of the excipients of the products, who is diagnosed as "severe or critical case" (e.g. pneumonia or severe pneumonia), whose national early warning score 2 (news2) score is indicated as "urgent" or "emergency", any history of bone marrow transplant, solid-organ transplant, immune compromising conditions, immunomodulatory therapy, haematologic malignancy, who have multiple sclerosis, who have electrolyte imbalance, chronic haemodialysis or glomerular filtration rate < 30 30 ml/min/1.73m2, who have history of serious cardiovascular diseases, who are diagnosed with another ongoing viral infection other than sars cov-2, who have macrophage activation syndrome, who have a need for coagulopathy treatment, who have severe liver disease, who is pregnant or nursing, who are not suitable to 1st articles of inclusion criteria, who is not eligible to swallow oral medications, who use vitamin c as supplementary medication during the study, who are included in another trial.

1. who have allergy to niclosamide and/or any of the treatment agents and/or any of the excipients of the products, 2. who is diagnosed as "severe or critical case" (e.g. pneumonia or severe pneumonia), 3. whose national early warning score 2 (news2) score is indicated as "urgent" or "emergency", 4. any history of bone marrow transplant, solid-organ transplant, immune compromising conditions, immunomodulatory therapy, haematologic malignancy, 5. who have multiple sclerosis, 6. who have electrolyte imbalance, chronic haemodialysis or glomerular filtration rate < 30 30 ml/min/1.73m2, 7. who have history of serious cardiovascular diseases, 8. who are diagnosed with another ongoing viral infection other than sars cov-2, 9. who have macrophage activation syndrome, 10. who have a need for coagulopathy treatment, 11. who have severe liver disease, 12. who is pregnant or nursing, 13. who are not suitable to 1st articles of inclusion criteria, 14. who is not eligible to swallow oral medications, 15. who use vitamin c as supplementary medication during the study, 16. who are included in another trial.

1. who have allergy to niclosamide and/or any of the treatment agents and/or any of the excipients of the products, 2. who is diagnosed as "severe or critical case" (e.g. pneumonia or severe pneumonia), 3. whose national early warning score 2 (news2) score is indicated as "urgent" or "emergency", 4. any history of bone marrow transplant, solid-organ transplant, immune compromising conditions, immunomodulatory therapy, haematologic malignancy, 5. who have multiple sclerosis, 6. who have electrolyte imbalance, chronic haemodialysis or glomerular filtration rate < 30 30 ml/min/1.73m2, 7. who have history of serious cardiovascular diseases, 8. who are diagnosed with another ongoing viral infection other than sars cov-2, 9. who have macrophage activation syndrome, 10. who have a need for coagulopathy treatment, 11. who have severe liver disease, 12. who is pregnant or nursing, 13. who are not suitable to 1st articles of inclusion criteria, 14. who is not eligible to swallow oral medications, 15. who use vitamin c as supplementary medication during the study, 16. who are included in another trial.